Pharmacoeconomic model to evaluate new influenza treatments

Edward P. Armstrong, Jacob Abarca

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Zanamivir and oseltamivir are two agents of a new class of drugs - neuraminidase inhibitors - to receive FDA approval for the treatment of influenza. Because the two agents are more expensive yet have a more favorable side effect profile than the older treatments amantadine and rimantidine, coverage decisions can be difficult to make. This month's column presents a decision-analytic model of influenza treatments, using zanamivir as the main example. This approach is helpful for health care systems that wish to assess clinical and economic outcomes to make informed decisions between competing products.

Original languageEnglish (US)
Pages (from-to)169-181
Number of pages13
Issue number2
StatePublished - Feb 2000

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Pharmacoeconomic model to evaluate new influenza treatments'. Together they form a unique fingerprint.

Cite this